查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
膀胱過動症治療(OAB)市場 - 佔有率，規模，趨勢，產業分析:各療法，各疾病類型，各地區，各市場區隔的預測(2022年～2030年)
市場調查報告書
商品編碼
1175595

膀胱過動症治療(OAB)市場 - 佔有率，規模，趨勢，產業分析:各療法，各疾病類型，各地區，各市場區隔的預測(2022年～2030年)

Overactive Bladder Treatment (OAB) Market Share, Size, Trends, Industry Analysis Report, By Therapy; By Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder); By Region; Segment Forecast, 2022-2030
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

全球膀胱過動症治療(OAB)的市場規模，預計至2030年達到52億美元。

本報告提供全球膀胱過動症治療(OAB)市場相關調查，詳細掌握目前市場動態，未來市場成長相關分析。

目錄

第1章 簡介

  • 報告的說明
    • 調查目的
    • 市場範圍
    • 前提
  • 利害關係者

第2章 摘要整理

  • 市場概況

第3章 調查手法

  • 概要
    • 資料探勘
  • 資料來源
    • 一次資訊
    • 二次資訊

第4章 全球膀胱過動症治療(OAB)市場洞察

  • 膀胱過動症治療(OAB)市場:產業概述
  • 膀胱過動症治療(OAB)市場動態
    • 促進因素和機會
    • 阻礙因素與課題
  • 波特的五力分析
    • 供給企業談判力(中度)
    • 新加入廠商的威脅(低)
    • 買方議價能力(中度)
    • 替代威脅(中度)
    • 現有企業間的競爭力(高)
  • 大環境分析
  • 膀胱過動症治療(OAB)產業趨勢
  • 價值鏈分析
  • COVID-19影響分析

第5章 全球膀胱過動症治療(OAB)市場:各疾病類型

  • 主要調查結果
  • 簡介
    • 全球膀胱過動症治療(OAB):各疾病類型(2018年～2030年)
  • 特發性膀胱過動症
    • 各地區(2018年～2030年)
  • 神經性膀胱過動症
    • 各地區(2018年～2030年)

第6章 全球膀胱過動症治療(OAB)市場:各治療法

  • 主要調查結果
  • 簡介
    • 全球膀胱過動症治療(OAB)市場:各治療法(2018年～2030年)
  • 抗膽鹼藥
    • 各地區(2018年～2030年)
  • Mirabegron
    • 各地區(2018年～2030年)
  • 神經刺激
    • 各地區(2018年～2030年)
  • 膀胱內注射
    • 各地區(2018年～2030年)
  • 其他
    • 各地區(2018年～2030年)

第7章 全球膀胱過動症治療(OAB)市場:各地區

  • 主要調查結果
  • 簡介
    • 膀胱過動症治療(OAB)的市場評估:各地區(2018年～2030年)
  • 膀胱過動症治療(OAB)市場:北美
    • 北美:各治療法(2018年～2030年)
    • 北美:各疾病類型(2018年～2030年)
    • 美國
    • 加拿大
  • 膀胱過動症治療(OAB)市場:歐洲
    • 歐洲:各治療法(2018年～2030年)
    • 歐洲:各疾病類型(2018年～2030年)
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
  • 膀胱過動症治療(OAB)市場:亞太地區
    • 亞太地區:各治療法(2018年～2030年)
    • 亞太地區:各疾病類型(2018年～2030年)
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
  • 膀胱過動症治療(OAB)市場:中東、非洲
    • 中東、非洲:各治療法(2018年～2030年)
    • 中東、非洲:各疾病類型(2018年～2030年)
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
  • 膀胱過動症治療(OAB)市場:南美
    • 南美:各治療法(2018年～2030年)
    • 南美:各疾病類型(2018年～2030年)
    • 墨西哥
    • 巴西
    • 阿根廷

第8章 競爭情形

  • 擴張和收購的分析
    • 擴張
    • 收購
  • 夥伴關係/合作/協定/展示會

第9章 企業簡介

  • AbbVie
  • Astellas Pharma
  • Laborie
  • Endo International PLC
  • Hisamitsu Pharmaceutical
  • Johnson & Johnson Services
  • Medtronic
  • Pfizer
  • Sanofi
  • Viatris
  • Teva Pharmaceutical
  • Hisamitsu
  • Johnson & Johnson
  • Macleods Pharmaceuticals
  • Urovant Sciences
  • Lupin
  • Uro Medical
  • Sun Pharmaceutical
  • Glenmark
  • Intas Pharmaceuticals
  • Bayer AG
  • Hugel
Product Code: PM2829

The global overactive bladder treatment market size is expected to reach USD 5.2 billion by 2030, according to a new study by Polaris Market Research. The report "Overactive Bladder Treatment (OAB) Market Share, Size, Trends, Industry Analysis Report, By Therapy; By Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder); By Region; Segment Forecast, 2022-2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing geriatric population and the prevalence of urinary incontinence are the key factors propelling the global market. The next-generation implant, sacral neuromodulation for OAB, is less risky, longer-lasting, and more user-friendly. For instance, in February 2022, the US health authorities approved Alembic Pharmaceutical's extended-release tablet, "Fesoterodine Fumarate," which treats individuals with overactive bladder symptoms. Fesoterodine fumarate extended-release tablets in strengths of 4 & 8 mg have also submitted ANDA application.

Furthermore, pharmaceutical and biopharmaceutical companies are now investing in cutting-edge medicines for the treatment of overactive bladders, which are anticipated to be introduced throughout the projected period. For instance, Taiho Pharmaceutical is working on the Phase II-ready medication TAC-302. This medication is orally accessible and works by promoting neurite outgrowth activity in cultured peripheral neurons to treat overactive bladder. When new treatment alternatives are introduced, more people will use them, increasing treatment uptake and so fueling market expansion.

A considerable portion of the population suffers from overactive bladder, a persistent medical problem. In the upcoming years, the market expansion might be constrained by frequent recalls of OAB-treating medications. AbbVie announced in February 2022 that the US FDA approved BOTOX treatment for the detrusor (bladder muscle) over-activity aligned with the neurologic condition in pediatric patients aged five or older who have a sub-optimal response to or the in-tolerable of anti-cholinergic medication. Regular recalls hampering market expansion for overactive bladder treatments by top pharmaceutical companies.

COVID-19 is anticipated to have a significant influence on the market for overactive bladder treatment. This is primarily brought on by the COVID-19 recovered patients' worsening overactive bladder symptoms. Several studies have referred to it as COVID-19-related cystitis (CAC). The market is therefore anticipated to show expansion during the anticipated period as a result of the aforementioned factors. However, the adverse consequences of the existing therapy can prevent the market from expanding.

Overactive Bladder Treatment Market Report Highlights

The market is anticipated to be dominated by Mirabegron in 2021. When compared to other pharmacological classes on the market, this industry's lower side-effect profile is one of its main growth drivers

The idiopathic overactive bladder segment retained a bigger market share in 2021, owing to the higher prevalence of idiopathic overactive bladder illnesses and the increasing use of pharmaceuticals for treatment.

The majority of the market was controlled by North America. The market is anticipated to expand throughout the course of the projection period because overactive bladder treatment is covered by insurance, the disease is anticipated to become more common as people age, and presence of large firms in the region.

The global players include AbbVie, Astellas Pharma, Laborie, Endo International PLC, Hisamitsu Pharmaceutical, Johnson & Johnson Services, Medtronic, Pfizer, Sanofi, and Viatris.

Polaris Market Research has segmented the Overactive Bladder Treatment Market report based on therapy, disease type, and region:

Overactive Bladder Treatment, Therapy Outlook (Revenue - USD Billion, 2018 - 2030)

Anticholinergics

Mirabegron

Neurostimulation

Intravesical Instillation

Other Therapies

Overactive Bladder Treatment, Disease Type Outlook (Revenue - USD Billion, 2018 - 2030)

Idiopathic Overactive Bladder

Neurogenic Overactive Bladder

Overactive Bladder Treatment, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Overactive Bladder Treatment (OAB) Market Insights

  • 4.1. Overactive Bladder Treatment (OAB) Market - Industry Snapshot
  • 4.2. Overactive Bladder Treatment (OAB) Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of overactive bladder syndrome
      • 4.2.1.2. Rising elderly population
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Frequent product recalls
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Overactive Bladder Treatment (OAB) Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Overactive Bladder Treatment (OAB) Market, by Disease Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Overactive Bladder Treatment (OAB), by Disease Type, 2018 - 2030 (USD Billion)
  • 5.3. Idiopathic Overactive Bladder
    • 5.3.1. Global Overactive Bladder Treatment (OAB) Market, by Idiopathic Overactive Bladder, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Neurogenic Overactive Bladder
    • 5.4.1. Global Overactive Bladder Treatment (OAB) Market, by Neurogenic Overactive Bladder, by Region, 2018 - 2030 (USD Billion)

6. Global Overactive Bladder Treatment (OAB) Market, by Therapy

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • 6.3. Anticholinergics
    • 6.3.1. Global Overactive Bladder Treatment (OAB) Market, by Anticholinergics, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Mirabegron
    • 6.4.1. Global Overactive Bladder Treatment (OAB) Market, by Mirabegron, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Neurostimulation
    • 6.5.1. Global Overactive Bladder Treatment (OAB) Market, by Neurostimulation, by Region, 2018 - 2030 (USD Billion)
  • 6.6. Intravesical Instillation
    • 6.6.1. Global Overactive Bladder Treatment (OAB) Market, by Intravesical Instillation, by Region, 2018 - 2030 (USD Billion)
  • 6.7. Other Therapies
    • 6.7.1. Global Overactive Bladder Treatment (OAB) Market, by Other Therapies, by Region, 2018 - 2030 (USD Billion)

7. Global Overactive Bladder Treatment (OAB) Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Overactive Bladder Treatment (OAB) Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 7.3. Overactive Bladder Treatment (OAB) Market - North America
    • 7.3.1. North America: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.3.2. North America: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.3.3. Overactive Bladder Treatment (OAB) Market - U.S.
      • 7.3.3.1. U.S.: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.3.3.2. U.S.: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.3.4. Overactive Bladder Treatment (OAB) Market - Canada
      • 7.3.4.1. Canada: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.3.4.2. Canada: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 7.4. Overactive Bladder Treatment (OAB) Market - Europe
    • 7.4.1. Europe: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.4.2. Europe: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.4.3. Overactive Bladder Treatment (OAB) Market - UK
      • 7.4.3.1. UK: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.4.3.2. UK: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.4.4. Overactive Bladder Treatment (OAB) Market - France
      • 7.4.4.1. France: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.4.4.2. France: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.4.5. Overactive Bladder Treatment (OAB) Market - Germany
      • 7.4.5.1. Germany: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.4.5.2. Germany: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.4.6. Overactive Bladder Treatment (OAB) Market - Italy
      • 7.4.6.1. Italy: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.4.6.2. Italy: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.4.7. Overactive Bladder Treatment (OAB) Market - Spain
      • 7.4.7.1. Spain: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.4.7.2. Spain: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.4.8. Overactive Bladder Treatment (OAB) Market - Netherlands
      • 7.4.8.1. Netherlands: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.4.8.2. Netherlands: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.4.9. Overactive Bladder Treatment (OAB) Market - Russia
      • 7.4.9.1. Russia: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.4.9.2. Russia: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 7.5. Overactive Bladder Treatment (OAB) Market - Asia Pacific
    • 7.5.1. Asia Pacific: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.5.2. Asia Pacific: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.5.3. Overactive Bladder Treatment (OAB) Market - China
      • 7.5.3.1. China: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.5.3.2. China: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.5.4. Overactive Bladder Treatment (OAB) Market - India
      • 7.5.4.1. India: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.5.4.2. India: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.5.5. Overactive Bladder Treatment (OAB) Market - Malaysia
      • 7.5.5.1. Malaysia: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.5.5.2. Malaysia: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.5.6. Overactive Bladder Treatment (OAB) Market - Japan
      • 7.5.6.1. Japan: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.5.6.2. Japan: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.5.7. Overactive Bladder Treatment (OAB) Market - Indonesia
      • 7.5.7.1. Indonesia: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.5.7.2. Indonesia: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.5.8. Overactive Bladder Treatment (OAB) Market - South Korea
      • 7.5.8.1. South Korea: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.5.8.2. South Korea: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 7.6. Overactive Bladder Treatment (OAB) Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.6.2. Middle East & Africa: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.6.3. Overactive Bladder Treatment (OAB) Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.6.4. Overactive Bladder Treatment (OAB) Market - UAE
      • 7.6.4.1. UAE: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.6.4.2. UAE: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.6.5. Overactive Bladder Treatment (OAB) Market - Israel
      • 7.6.5.1. Israel: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.6.5.2. Israel: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.6.6. Overactive Bladder Treatment (OAB) Market - South Africa
      • 7.6.6.1. South Africa: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.6.6.2. South Africa: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 7.7. Overactive Bladder Treatment (OAB) Market - Latin America
    • 7.7.1. Latin America: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.7.2. Latin America: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.7.3. Overactive Bladder Treatment (OAB) Market - Mexico
      • 7.7.3.1. Mexico: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.7.3.2. Mexico: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.7.4. Overactive Bladder Treatment (OAB) Market - Brazil
      • 7.7.4.1. Brazil: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.7.4.2. Brazil: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 7.7.5. Overactive Bladder Treatment (OAB) Market - Argentina
      • 7.7.5.1. Argentina: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
      • 7.7.5.2. Argentina: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AbbVie
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Astellas Pharma
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Laborie
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Endo International PLC
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Hisamitsu Pharmaceutical
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Johnson & Johnson Services
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Medtronic
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Pfizer
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Sanofi
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Viatris
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Teva Pharmaceutical
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Hisamitsu
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Johnson & Johnson
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Macleods Pharmaceuticals
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Urovant Sciences
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Lupin
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Uro Medical
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development
  • 9.18. Sun Pharmaceutical
    • 9.18.1. Company Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Recent Development
  • 9.19. Glenmark
    • 9.19.1. Company Overview
    • 9.19.2. Financial Performance
    • 9.19.3. Product Benchmarking
    • 9.19.4. Recent Development
  • 9.20. Intas Pharmaceuticals
    • 9.20.1. Company Overview
    • 9.20.2. Financial Performance
    • 9.20.3. Product Benchmarking
    • 9.20.4. Recent Development
  • 9.21. Bayer AG
    • 9.21.1. Company Overview
    • 9.21.2. Financial Performance
    • 9.21.3. Product Benchmarking
    • 9.21.4. Recent Development
  • 9.22. Hugel
    • 9.22.1. Company Overview
    • 9.22.2. Financial Performance
    • 9.22.3. Product Benchmarking
    • 9.22.4. Recent Development

List of Tables

  • Table 1 Global Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 2 Global Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 3 Overactive Bladder Treatment (OAB) Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 4 North America: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 5 North America: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 6 U.S.: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 7 U.S.: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 8 Canada: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 9 Canada: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 10 Europe: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 11 Europe: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 12 UK: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 13 UK: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 14 France: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 15 France: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 16 Germany: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 17 Germany: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 18 Italy: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 19 Italy: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 20 Spain: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 21 Spain: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 22 Netherlands: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 23 Netherlands: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 24 Russia: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 25 Russia: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 26 Asia Pacific: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 27 Asia Pacific: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 28 China: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 29 China: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 30 India: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 31 India: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 32 Malaysia: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 33 Malaysia: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 34 Japan: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 35 Japan: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 36 Indonesia: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 37 Indonesia: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 38 South Korea: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 39 South Korea: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 40 Middle East & Africa: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 41 Middle East & Africa: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 42 Saudi Arabia: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 43 Saudi Arabia: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 44 UAE: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 45 UAE: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 46 Israel: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 47 Israel: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 48 South Africa: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 49 South Africa: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 50 Latin America: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 51 Latin America: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 52 Mexico: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 53 Mexico: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 54 Brazil: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 55 Brazil: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 56 Argentina: Overactive Bladder Treatment (OAB) Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 57 Argentina: Overactive Bladder Treatment (OAB) Market, by Disease Type, 2018 - 2030 (USD Billion)

List of Figures

Figure 1 Global Overactive Bladder Treatment (OAB) Market, 2018 - 2030 (USD Billion)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top-Down & Bottom-Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Therapy

Figure 7 Global Overactive Bladder Treatment (OAB) Market, by Therapy, 2021 & 2030 (USD Billion)

Figure 8 Market by Disease Type

Figure 9 Global Overactive Bladder Treatment (OAB) Market, by Disease Type, 2021 & 2030 (USD Billion)

Figure 10 Overactive Bladder Treatment (OAB) Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 11 Strategic Analysis - Overactive Bladder Treatment (OAB) Market